comparemela.com

Page 15 - Nasdaq Ntra News Today : Breaking News, Live Updates & Top Stories | Vimarsana

EPAM Systems (NYSE:EPAM) PT Lowered to $350 00 at Susquehanna

Natera (NASDAQ:NTRA – Get Rating) had its price objective hoisted by Credit Suisse Group from $65.00 to $70.00 in a research note released on Wednesday morning, The Fly reports. A number of other equities analysts have also recently commented on the stock. UBS Group started coverage on shares of Natera in a research note on […]

Natera (NASDAQ:NTRA) Issues Quarterly Earnings Results

Natera (NASDAQ:NTRA – Get Rating) posted its quarterly earnings results on Tuesday. The medical research company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.18) by ($0.05), Briefing.com reports. Natera had a negative net margin of 66.79% and a negative return on equity of 106.67%. The business had revenue […]

S&P Global Inc (NYSE:SPGI) Holdings Increased by Intermede Investment Partners Ltd

Natera (NASDAQ:NTRA – Get Rating) issued its earnings results on Tuesday. The medical research company reported ($1.23) EPS for the quarter, missing the consensus estimate of ($1.18) by ($0.05), Briefing.com reports. The company had revenue of $241.76 million for the quarter, compared to analysts’ expectations of $227.43 million. Natera had a negative return on equity […]

Natera (NASDAQ:NTRA) Releases Quarterly Earnings Results, Misses Estimates By $0 05 EPS

Natera (NASDAQ:NTRA – Get Rating) posted its quarterly earnings results on Tuesday. The medical research company reported ($1.23) EPS for the quarter, missing the consensus estimate of ($1.18) by ($0.05), Briefing.com reports. Natera had a negative return on equity of 106.67% and a negative net margin of 66.79%. The company had revenue of $241.76 million […]

Natera (NASDAQ:NTRA) Coverage Initiated by Analysts at UBS Group

UBS Group initiated coverage on shares of Natera (NASDAQ:NTRA – Get Rating) in a research report report published on Friday morning, The Fly reports. The firm issued a buy rating and a $76.00 target price on the medical research company’s stock. Other equities analysts have also issued reports about the stock. Piper Sandler lifted their […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.